Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21673670 | 1.00 | SIGMAR1 (0.39) | SIGMAR1KCNJ1KCNH2GBA1DRD3 | |
| SCHEMBL23875168 | 1.00 | SIGMAR1 (0.39) | SIGMAR1KCNJ1KCNH2GBA1DRD3 | |
| SCHEMBL26972455 | 0.94 | SIGMAR1 (0.43) | SIGMAR1KCNJ1KCNH2DRD3DRD2 | |
| SCHEMBL25133361 | 0.94 | SIGMAR1 (0.43) | SIGMAR1KCNJ1KCNH2DRD3DRD2 | |
| SCHEMBL25608578 | 0.89 | KCNJ1 (0.39) | SIGMAR1KCNJ1KCNH2GBA1DRD3 | |
| SCHEMBL23205043 | 0.89 | KCNJ1 (0.39) | SIGMAR1KCNJ1KCNH2GBA1DRD3 | |
| SCHEMBL23205219 | 0.86 | SIGMAR1 (0.37) | SIGMAR1KCNJ1KCNH2KDM1APOLB | |
| SCHEMBL23267012 | 0.86 | SIGMAR1 (0.37) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL23205217 | 0.86 | SIGMAR1 (0.40) | SIGMAR1KCNJ1KCNH2 | |
| SCHEMBL25133363 | 0.85 | SIGMAR1 (0.35) | SIGMAR1KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | SIGMAR1 3355/4885KCNJ1 4833/4885KCNH2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.